Not only have record numbers of new cases been registered this week in at least 7 states, test positivity has increased, hospitalizations have doubled this month in several hotspot states, and ICU unit usage is rising. It also appears that the decline in numbers of daily deaths has stalled.
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Cannabis is widely used by patients with cancer to help with cancer symptoms and treatment side effects. Though cannabis has immunomodulatory effects, and its consumption…
/PRNewswire-PRWeb/ — Protean BioDiagnostics is proud to announce its partnership with Travera. As one of Travera’s first Center of Excellence, the partnership…
Protean’s new partnership with Travera will bring expanded treatment options to advanced carcinoma patients and their physicians.
ChromaCode has entered into a partnership with Protean BioDiagnostic for the launch of a non-small cell lung cancer (NSCLC) assay in the US.
Protean is excited to partner with ChromaCode, Inc., to bring innovative cancer diagnostic technologies to oncologists and patients!
